Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Amortization - Deferred ChargesCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Innoviva (INVA) Long-Term Debt Issuances (2013 - 2022)

Innoviva posted quarterly Long-Term Debt Issuances of $252.5 million for Q3 2022, up 98746.88% on a QoQ basis from -$256000.0 in Q2 2022.

Innoviva (INVA) has 3 years of Long-Term Debt Issuances data on file, last reported at $252.5 million in Q3 2022.

  • For the quarter ending Q3 2022, Long-Term Debt Issuances changed N/A year-over-year to $252.5 million; the trailing twelve-month figure through Sep 2023 stood at $252.5 million (down 50.0% YoY), and the FY2022 full-year result was $252.5 million, changed N/A from the prior year.
  • Long-Term Debt Issuances for Q3 2022 stood at $252.5 million, up from -$256000.0 in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $252.8 million in Q1 2022 and bottomed at -$256000.0 in Q2 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 2.73 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Innoviva 1.60 Bn 992.84 Mn 75.83 Mn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2022 252.54 Mn
Sep 30, 2022 252.54 Mn
Jun 30, 2022 -256,000.00
Jun 30, 2022 -256,000.00
Mar 31, 2022 252.79 Mn
Mar 31, 2022 252.79 Mn
Jun 30, 2014 -23,000.00
Jun 30, 2014 -23,000.00
Sep 30, 2013 -1,000.00
Sep 30, 2013 -1,000.00
Jun 30, 2013 -50,000.00
Jun 30, 2013 -50,000.00
Mar 31, 2013 281.67 Mn
Mar 31, 2013 281.67 Mn